We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lead‑203 VMT‑α‑Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.
- Authors
Thakral, Parul; Sen, Ishita Barat; Das, Subha Shankar; Schultz, Michael K.; Kumari, Jyotsna; C. B., Virupakshappa; Malik, Dharmender
- Abstract
Targeted alpha therapy (TAT) using lead‑212 (Pb‑212)‑labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb‑203 presents an accurate diagnostic surrogate to Pb‑212, imaging with Pb‑203‑labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb‑212‑labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb‑203 VMT‑α‑NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb‑203 VMT‑α‑NET with Ga‑68 DOTANOC.
- Subjects
RADIONUCLIDE imaging; SOMATOSTATIN receptors; NEUROENDOCRINE tumors; COMPANION diagnostics; PEPTIDES
- Publication
Indian Journal of Nuclear Medicine, 2024, Vol 39, Issue 2, p142
- ISSN
0972-3919
- Publication type
Article
- DOI
10.4103/ijnm.ijnm_2_23